Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
benzodiazepine
sedative-hypnotic drug |
| gptkbp:ATCCode |
N05CA03
|
| gptkbp:brand |
Amytal
|
| gptkbp:CASNumber |
57-43-2
|
| gptkbp:category |
benzodiazepine
anticonvulsant hypnotic barbiturate derivative GABA_A receptor positive allosteric modulator barbiturate sedative World Health Organization essential medicine (historical) |
| gptkbp:chemicalFormula |
C11H18N2O3
|
| gptkbp:color |
white
|
| gptkbp:contraindication |
porphyria
severe respiratory insufficiency history of addiction |
| gptkbp:discoveredBy |
Augustus Desire Waller
|
| gptkbp:eliminationHalfLife |
8–42 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Amobarbital
|
| gptkbp:introducedIn |
1923
|
| gptkbp:IUPACName |
5-ethyl-5-(3-methylbutyl)barbituric acid
|
| gptkbp:legalStatus |
gptkb:Schedule_II_controlled_substance
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
226.27 g/mol
|
| gptkbp:notRecommendedFor |
elderly
long-term use |
| gptkbp:pregnancyCategory |
D
|
| gptkbp:produces_effect |
sedation
central nervous system depression sleep induction |
| gptkbp:PubChem_CID |
2075
2161 CHEMBL1201192 |
| gptkbp:riskFactor |
addiction
overdose withdrawal symptoms |
| gptkbp:routeOfAdministration |
oral
intramuscular intravenous |
| gptkbp:sideEffect |
drowsiness
respiratory depression dependence |
| gptkbp:solubility |
slightly soluble
|
| gptkbp:synonym |
Amytal sodium
amylobarbitone amylobarbituric acid |
| gptkbp:UNII |
G15YON7B6B
|
| gptkbp:usedFor |
sedation
treatment of insomnia preanesthetic |
| gptkbp:bfsParent |
gptkb:Barbiturates
|
| gptkbp:bfsLayer |
7
|